This document discusses medical management options for dysfunctional uterine bleeding (DUB). It begins by defining DUB and outlining treatment goals of controlling bleeding, correcting related conditions, preventing recurrence, and improving quality of life. First line treatment is recommended to be a levonorgestrel-releasing intrauterine system. Other options discussed include tranexamic acid, NSAIDs, combined oral contraceptives, and various progestogen therapies. Ormeloxifene is presented as an ideal selective estrogen receptor modulator for DUB due to its tissue-specific effects and safety profile. Studies demonstrate its effectiveness in reducing bleeding and improving outcomes for women with DUB.
Introduction
Pregnancy is a normal physiological process and any intervention that is offered to the pregnant or expectant mother should have known benefits and should be acceptable to the woman
Screening in pregnancy is the process of surveying a population of women with markers and defined screening cut-off levels, to identify those at higher risk for a particular disorder
All pregnant women, regardless of age, should be offered, through an informed counselling process, the option of a prenatal screening test for the most common clinically significant fetal aneuploidies
Introduction
Pregnancy is a normal physiological process and any intervention that is offered to the pregnant or expectant mother should have known benefits and should be acceptable to the woman
Screening in pregnancy is the process of surveying a population of women with markers and defined screening cut-off levels, to identify those at higher risk for a particular disorder
All pregnant women, regardless of age, should be offered, through an informed counselling process, the option of a prenatal screening test for the most common clinically significant fetal aneuploidies
Women with benign heavy menstrual bleeding have the choice of a number of medical treatment options to reduce their blood loss and improve quality of life.
Presentation on the description of normal and abnormal uterine bleeding, menstrual cycle, FIGO classification with PALM-COEIN, common differentials of AUB, assessment, diagnosis, and management.
Women with benign heavy menstrual bleeding have the choice of a number of medical treatment options to reduce their blood loss and improve quality of life.
Presentation on the description of normal and abnormal uterine bleeding, menstrual cycle, FIGO classification with PALM-COEIN, common differentials of AUB, assessment, diagnosis, and management.
Uterine Fibroids: Symptoms, Causes, Risk Factors & Treatment uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer
A benign tumor of muscular and fibrous tissues, typically developing in the wall of the uterus.
Prevalence varies among studies and countries (4.5-68.6%)
Nearly 20-30% Indian women in reproductive age group have fibroid uterus
At any given time, nearly 15-25 million Indian women have fibroid uterus
Understand fibroids in a better way
International Journal of Pharmaceutical Science Invention (IJPSI)inventionjournals
International Journal of Pharmaceutical Science Invention (IJPSI) is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online
Role of progestogens in obstetrics and gynecologyAhmad Saber
The
different progestogens with their overlapping effects on estrogen, androgen, glucocorticoid,
and mineralocorticoid receptors are described in order to allow the clinician to make the most appropriate choice of progestogen.
Dydrogesterone versus progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials
M. W. P. Barbosa, L. R. Silva, P. A. Navarro, R. A. Ferriani, C. O. Nastri and W. P. Martins
Volume 48, Issue 2, Pages 161–170
Slides prepared by Dr Aly Youssef (UOG Editor for Trainees)
Link to free-access article: http://onlinelibrary.wiley.com/doi/10.1002/uog.15814/full
The Newer Concepts In Endometriosis Management : Dr Sharda JainLifecare Centre
The Newer Concepts In
Endometriosis Management
ENDOMETRIOSIS IS ENIGMA
DIAGNOSTIC DELEMMA
DEBILITATING DISEASE QOL
PROGRESSIVE DISEASE
RECURRENCE IS BIG PROBLEM
NO FINAL VERDICT ON CAUSE
NO PERMANENT CURE
The exact prevalence of endometriosis is unknown, but estimates 10% in the general female population in India but up to 50% in infertile women
The Newer Concepts forReduced Surgery to preserve fertility in Endometrios...Lifecare Centre
The Newer Concepts forReduced Surgery to preserve fertility in Endometriosis
ENDOMETRIOSIS IS ENIGMA
DIAGNOSTIC DILEMMA
DEBILITATING DISEASE QOL
PROGRESSIVE DISEASE
RECURRENCE IS BIG PROBLEM
NO FINAL VERDICT ON CAUSE
NO PERMANENT CURE
The exact prevalence of endometriosis is unknown, but estimates 10% in the general female population in India but up to 50% in infertile women
Anemia Free India Gynaecologist to focuss on *12gm Haemoglobin at Delivery I...Lifecare Centre
Important Highlights
Prophylactic Iron and Folic Acid Supplementation in all six target age groups.
Intensified year-round Behaviour Change Communication (BCC) Campaign for:(a) improving compliance to IFA and deworming, (b) enhancing appropriate infant and young child feeding practices, (c) encouraging increase in intake of iron-rich food through diet and/or fortified foods (d) ensuring delayed cord clamping .
Testing and treatment of anaemia, using digital methods and point of care treatment, with special focus on pregnant women and school-going adolescents.
Addressing non-nutritional causes of anaemia
in endemic pockets with special focus on malaria, hemoglobinopathies and fluorosis
Strategies for Improving Success Rates in ART PARTLifecare Centre
Strategies for Improving Success Rates in ART
Part - 2
Strategies for Improving Success Rates in ART
Tailoring Controlled Ovarian Stimulation
Strategies for Luteal Phase in ART cycles
Endometrial Receptivity Array
How to optimize success rates in ART? : Dr Sharda JainLifecare Centre
How to optimize success rates in ART? : Dr Sharda Jain
How to improve success rates in ART?
The big debate कार्य में आनंद
Evolution of In-vitro Fertilization (IVF)
Factors Influencing IVF Success Ist Part
Strategies for Improving Success Rates in ART Second Part
Innovations & Breakthroughs in IVF Part Three
OPEN DEBATE
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda JainLifecare Centre
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda Jain
Introduction
Social egg freezing (oocyte cryopreservation for non-medical reasons) has evolved as a proactive option for women looking to extend their reproductive possibilities past their peak childbearing years
It is the process of saving or protecting eggs, or reproductive tissues so that a person can use them to have biological children in future
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Medical management of dub – new modalities
1. MEDICAL MANAGEMENT
OF DUB – NEW
MODALITIES
Dr.Jyoti Bhaskar
MD MRCOG
Director Lifecare IVF
Consultant
Lifecare Centre, Pushpanjali Crosslay Hospital
Lecture 2 (2013)
Save Uterus Campaign
2. Definition Of HMB
“Excessive menstrual blood loss which
interferes with the woman’s physical,
emotional, social and material quality of
life, and which can occur alone or in
combination with other symptoms.”
Nice guidelines 2007
3. Treatment of DUB
Woman Centred Care
Goals
Control bleeding
Correct anemia/associated conditions
Prevent recurrence
Improve quality of life
Any interventions should aim to improve quality of life measures.
[D] -- NICE guidelines
5. Ideal Treatment Choice–Points toIdeal Treatment Choice–Points to
PonderPonder
Whether cycles are
ovulatory or not
Age
Whether the patient requires
contraception
Desires Fertility
Choice of the patient
6. First Line Levonorgestrel-releasing intrauterine
system (LNG-IUS)
Second Line Tranexamic acid (non-hormonal)
Can be used in parallel with investigations. If
no improvement, stop treatment after 3 cycles
Non-steroidal anti-inflammatory drugs (NSAIDs)
If no improvement, stop treatment after 3 cycles.
Can be used in parallel with investigations
Preferred over tranexamic acid in dysmenorrhoea
Combined oral contraceptives
Pharmaceutical Treatment – Nice Guidelines
7. Third Line Oral progestogen
Norethisterone (15 mg) daily from days 5 to
26 of the menstrual cycle
Injected progestogen
Others Gonadotrophin-releasing hormone
analogue (Gn-RH analogue)
If used for more than 6 months add back
HRT therapy is recommended
8. Following Treatment Not Recommended
Oral progestogens in the luteal phase
only
Danazol
Ethamsylate
Dilatation and curettage (D and C)
9. GUIDELINES FOR THE MANAGEMENT OF
ABNORMAL UTERINE BLEEDING
Age, desire to preserve fertility, coexisting medical
conditions, and patient preference are essential
considerations.
For each of the suggested methods, the patient should
be aware of the risks and contraindications to allow
informed choice.
Progestogens given in the luteal phase of the
ovulatory menstrual cycles are not effective in
reducing regular heavy menstrual bleeding.
S O G C C L I N I C A L P R A C T I C E G U I D E L I N E S 2001
13. “The ideal therapy should be a
designer drug which can block
the action of estrogen on the
endometrium but not its beneficial
actions on other tissues”
Need of the Hour --- Medical DrugsNeed of the Hour --- Medical Drugs
15. IDEAL SERM FOR DUBIDEAL SERM FOR DUB
“An optimally designed SERM with Varied Tissue Response”
16. Ormeloxifene – An Ideal SERMOrmeloxifene – An Ideal SERM
Dysfunctional uterine bleeding at any age
Relief of PMS in perimenopausal women
For women desiring contraceptive property
Has an excellent safety profile, very well-tolerated &
practically without any undesirable side-effects
17. Ormeloxifene– Dosing StrategyOrmeloxifene– Dosing Strategy
Convenient dosage – twice or once weekly
60 mg tablets twice a week ( for example, Sunday &
Wednesday) for 12 weeks followed by one tablet of 60 mg
once a week for another 12 weeks
18. Ormeloxifene
CDR Institute Lucknow 1991
Once a week Non Hormonal
Contraceptive
Marketed in India in 1992 as
Saheli and Choice-7 and
Centron
Included in the National Family
Welfare Programme in 1995
19. Efficacy in Dysfunctional Menorrhagia (AIIMS)Efficacy in Dysfunctional Menorrhagia (AIIMS)
PILOT STUDYPILOT STUDY
Study Population: Forty-two women with menorrhagia were recruited for the
study
Dosage: Ormeloxifene was given to each patient 60 mg twice a week for 3
months and then once a week for 1 month. Patients were followed up at 2
and 4 months of therapy, then at 3 and 6 months after treatment was stopped
Assessments:
Menstrual blood loss (MBL) was measured objectively by a pictorial
blood loss assessment chart (PBAC) score and subjectively by a
visual analog scale (VAS)
J. Obstet. Gynaecol. Res. vol. 35, No. 4: 746–752, August 2009
20. Efficacy in Dysfunctional MenorrhagiaEfficacy in Dysfunctional Menorrhagia
The pretreatment median PBAC
score was 388 (range 169–835)
Median PBAC reduced to 80
(range 0–730) and 5 (range 0–
310) at 2 and 4 months,
respectively (p-value <0.001)
The percentage reduction in
PBAC score - 97.7% at 4
months
J. Obstet. Gynaecol. Res. vol. 35, No. 4: 746–752, August 2009
Reduction in PBAC Score
21. Efficacy in Dysfunctional MenorrhagiaEfficacy in Dysfunctional Menorrhagia
Amenorrhea with the
therapy – 18 patients
(42.9%)
Adverse effects included
ovarian cyst (7.1%),
cervical erosion and
discharge (7.1%), gastric
dyspepsia (4.8%), vague
abdominal pain (4.8%) and
headache (4.8%)
J. Obstet. Gynaecol. Res. Vol. 35, No. 4: 746–752, August 2009
Percentage Reduction in PBAC ScorePercentage Reduction in PBAC Score
97.7%97.7%
2.3%2.3%
22. Ormeloxifene Versus MPA in the treatment of
Dysfunctional uterine Bleeding : A Double- Blind
Randomised Controlled Trial
Journal of South Asian Federation of obstetrics and Gynaecology Jan –April 2011
.Study Population: 84 women attending gynae OPD in Belgaum India were
enrolled , 42 in each arm.
Dosage: Group A – 60 mg ormeloxifene twice a week for 3 consecutive cycles
and Group B – 10 mg MPA from day 5-25 for 3 cycles. All were made to use
same type of sanitary napkins and TVS done for ET before and after treatment
Data Analysis : Mean PBAC score and endometrial thickness were compared
Result: Mean PBAC score reduction of 85.7 % and 54% in group A and B resp
ET reduction was more in Ormeloxifene group but not statistically sign.
Conclusion: oremloxifene is more effective in reducing bleeding than MPA
23. Role of Sevista in the Management of
Dysfunctional Uterine Bleeding
Study Population: 35 cases diagnosed to have DUB after having ruled out
other causes
Dosage: Ormeloxifene was given in the dosage of a 60 mg tablet twice a week
for 3 months, followed by once a week for another 3 months.
Assesment : Hb g/dl and the endometrial thickness before and after 3
months of treatment with sevista.
Observation & results: Statistically significant increase in the Hb g/dl (p <
0.001) and a statistically significant decrease in the endometrial thickness
(p< 0.001) after the treatment with ormeloxifene.
Dhananjay BS, Sunil Kumar Nanda , Journal of Clinical and Diagnostic Research, 2012.
Conclusion: Ormeloxifene can be used as an effective drug in
the treatment of Dysfunctional uterine bleeding
24. Our Experience ( Over 500 cases)
Indications
1. Puberty Mennorhagia
2. Postnatal Bleeding
3. DUB- after TVS r/o Ovarian Cyst
Dose- 60mg twice weekly for 3months.
Effective upto 1 year after stopping it.
25. Held Back
1. Postmenopausal Bleeding
2. Endometrial Hyperplasia
3. Infertile patients
4. PCOS
Special mention:
1. In PMB , after balloon therapy – once a week
for 3 months
2. In hyperplasia – along with progesterone's
28. Breaking Myths with Scientific EvidenceBreaking Myths with Scientific Evidence
No effect on hypothalmo-pituitary-ovarian axis
Its effect as a contraceptive is local with no effect on hypothalmo-
pituitary-ovarian axis
No effect on ovulation
It does not affect ovulation as evidenced by good luteal activity, but
causes an increase in cycle length by lengthening the follicular phase.
Its contraceptive action is primarily due to the prevention of
endometrial decidualization and failure of implantation
J. Obstet Gynaecol Res. Vol. 35, No. 4: 746–752, August 2009.
29. Breaking Myths with Scientific EvidenceBreaking Myths with Scientific Evidence
It does not cause cystic enlargement of ovaries
It is reported that only 15% patients may develop these, which
disappear in subsequent cycles. In the study by Kriplani et al, ovarian
enlargement was found only in three patients (7.1%)
It does not cause endometrial thickness
In the study by Kriplani et al, increased endometrial thickness was
found in 9.5% of patients, but there was no atypia on histology.
J. Obstet Gynaecol Res. vol. 35, No. 4: 746–752, August 2009.
30. Conclusions
First Line of management of DUB should be
pharmaceutical
Available medical modalities are far from satisfactory
Important to individualize the treatment
Mirena is the first line of treatment – Nice Guidelines
Ormeloxifene is safe, efficacious, cheap and easy to
administer.
31. Thank YouThank You
THANK YOU
Making one person smile can change the world.
May be not the whole world but their world..
33. Ideal SERM for DUBIdeal SERM for DUB
Ideal SERM for DUB is one that has
No uterine stimulation
Prevents bone loss
Has no risk for breast cancer
Has a positive effect on lipids &
cardiovascular system
Maintains cognitive function of the
brain
Estrogen in CNS
Antiestrogen in
the breast
No DNA adducts
Lowers cholesterol
No uterine
stimulation
Maintains
bone density
34. SERM’s – The Designer EstrogensSERM’s – The Designer Estrogens
Depending on their functional activities, SERMs could then
be developed for a variety of clinical uses, including
Prevention and treatment of osteoporosis
Treatment and prevention of estrogen-regulated
malignancies
Fibrofatty disease of breast and mastalgia
J Clin Oncol 2000 18:3172-3186.
35. Levonorgestrel Intrauterine System
Cost limits its widespread use
Irregular bleeding in the first 3 months and
leads to amenorrhea 15-20% of patients by 1
year
Needs to be changed every 5 years
It acts as a contraception and cannot be used
in women desiring pregnancy.
First line of treatment in DUB – Nice
guidelines
36. Ormeloxifene
Central Drug Research Institute, Lucknow, is a nonsteroidal once-a-
week oral contraceptive.
It was introduced in Delhi in July, 1991, marketed in India in 1992 as
Saheli and Choice-7 and Centron
Included in the National Family Welfare Programme in 1995.
100,000 women were using this pill and apprx 1100,000 menstrual
cycles were covered until 1996
Long terminal serum half life of 168 hr in women and exhibits
duration of anti-implantation/estrogen antagonistic action of 120 hr.
In lactating women, it is excreted in milk in quantities considered
unlikely to cause any deleterious effect on suckling babies
Med Res Rev. 2001 Jul;21(4):302-47.
38. ADDRESS
35 , Defence Enclave, Opp. Preet Vihar
Petrol Pump, Metro pillar no. 88, Vikas
Marg , Delhi – 110092
CONTACT US
011-22414049, 42401339
WEBSITE :
www.lifecarecentre.in
www.drshardajain.com
www.lifecareivf.com
E-MAIL ID
Sharda.lifecare@gmail.com
Lifecarecentre21@gmail.com
info@lifecareivf.com
&
Editor's Notes
Once DUB has been diagnosed and pathologic causes ruled out, there are several goals of therapy. No single method is always effective. Many factors play a role in the decision to begin one therapy over another: age, severity of bleeding, no. of children, desire for fertility presence of associated pelvic pathology
Inevitably, a profuse but painless menstrual bleed frightens the patient into seeking medical help. It is paramount that the treating clinician probes the following aspects before initiating the treatment. Several treatment aspects will be discussed in the subsequent slides. Although many of them look promising there are some serious concerns, which should be clearly understood by the clinician.
Some of the agents for the chronic treatment of DUB include progestational agents, clomiphene citrate, antiprostaglandins, danozol and GnRH analogs. Surgical management may include hysterectomy or less invasive, uterus-sparing procedures. Reference: Ferri: Ferri's Clinical Advisor 2010, 1st ed.
Medical therapy discussed in the previous slides although quite effective, have several limitations. This can be attributed to their direct estrogenic and progesterone action. Research has focused on compounds that are selective for specific tissues thereby minimizing the unwanted effects in some areas and augmenting action in necessary tissues. The ideal therapy to treat DUB should be a designer drug, which can block the action of estrogen on the endometrium, but not its beneficial actions on other tissues.
Estrogens have agonistic or stimulating effects on all of the estrogen receptor sites Antiestrogens at the other end of the spectrum have antagonistic effects on the same sites. SERM’s like tomoxifine, ormeloxifene are designed to act in specific ways at each of the receptor sites. Reference: J Clin Oncol 2000 18:3172-3186.
Ormeloxifene is a nonsteroidal, SERM and has been in use as a weekly oral contraceptive for approximately last 20 years, particularly in India, where it was originally developed. Ormeloxifene interacts with ER, eliciting tissue-specific responses. It is also undergoing clinical evaluation for the treatment of advanced breast cancer and the prevention of osteoporosis due to its potent antiestrogenic, weak estrogenic and antiprogestational activities. Reference: Ormeloxifene (Sevista) Product Monograph. Data on file.
In line with the features discussed earlier, ormeloxifene has all the characteristics of an ideal SERM. Key points are highlighted in this slide. Reference: Ormeloxifene (Sevista) Product Monograph. Data on file.
Ormeloxifene can be given as 2 tablets of 60 mg twice a week; every Sunday and Wednesday for the first 12 weeks and then one tablet of 60 mg on the following Sunday/Wednesday for 12 weeks. Reference: Ormeloxifene (Sevista) Product Monograph. Data on file.
In another clinical study 42 women with menorrhagia were studied. Ormeloxifene was given to each patient, 60 mg, twice a week for 3 months and then once a week for 1 month. Patients were followed up at 2 and 4 months of therapy, then at 3 and 6 months after the treatment was stopped. Investigators measured menstrual blood loss objectively by a PBAC score and subjectively by a Visual Analog scale. Reference: J. Obstet. Gynaecol. Res . vol. 35, No. 4: 746–752, August 2009.
The pretreatment median PBAC score was 388 (range 169–835). Eighteen patients (42.9%) had amenorrhea with the therapy. Median PBAC reduced to 80 (range 0–730) and 5 (range 0–310) at 2 and 4 months, respectively (p-value <0.001). Reference: J. Obstet. Gynaecol. Res. vol. 35, No. 4: 746–752, August 2009
The percentage reduction in the PBAC score was 97.7% at 4 months. Adverse effects included ovarian cyst (7.1%), cervical erosion and discharge (7.1%), gastric dyspepsia (4.8%), vague abdominal pain (4.8%) and headache (4.8%). Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia. Reference: J. Obstet. Gynaecol. Res . Vol. 35, No. 4: 746–752, August 2009.
There were several myths around the treatment with ormeloxifene. Research has proven that these myths are indeed not true. For contraception, centchroman (ormeloxifene) is given at a weekly dose of 30 mg/week after a twice-weekly loading dose for 12 weeks to build up adequate blood levels to prevent failures in the beginning of the therapy due to inadequate steady state concentrations. Its effect is local with no effect on hypothalmo–pituitary–ovarian axis. In healthy females, it does not affect ovulation as evidenced by good luteal activity, but causes an increase in cycle length by lengthening the follicular phase. Its contraceptive action is primarily due to the prevention of endometrial decidualization and failure of implantation. Reference: J. Obstet Gynaecol Res . Vol. 35, No. 4: 746–752, August 2009.
Although there is the concern of cystic enlargement of ovaries, it is reported that only 15% patients may develop these, which disappear in subsequent cycles. In the study by Kriplani et al. , ovarian enlargement was found only in three patients (7.1%). Increased endometrial thickness observed has been documented in 40% of cases with levormeloxifene. In the study by Kriplani et al ., increased endometrial thickness was found in 9.5% of patients, but there was no atypia on histology, which corroborates well with previous studies in which the authors did not document any endometrial hyperplasia with atypia. Evaluation of endometrium in one study revealed hyperplasia in only 2.6% of cases and most of the cases had a secretory, proliferative or a decidual pattern. Reference: J. Obstet Gynaecol Res . vol. 35, No. 4: 746–752, August 2009.
An ideal SERM for DUB should not cause uterine stimulation. There should be no bone loss and the risk of breast cancer. It should have a positive effect on patients with cardiovascular diseases. Some compounds can affect the HDL and LDL levels there by jeopardizing the health of patients with cardiovascular diseases. Maintaining cognitive functions is also paramount.
SERMs bind ER, alter receptor conformation and facilitate binding of coregulatory proteins that activate or repress transcriptional activation of estrogen target genes. Depending on their functional activities, SERMs could then be developed for a variety of clinical uses like DUB, osteoporosis, cancer, etc. Reference: J Clin Oncol 2000 18:3172-3186
High-dose progestin therapy, for example, 5-mg tablets of norethindrone acetate reduces ovarian estradiol production, but long-term use can be associated with loss of bone density. This therapy can reduce high-density lipoprotein (HDL) and increase low-density lipoprotein (LDL) levels and should be used carefully in patients with cardiovascular disorders. The levonorgestrel intrauterine system is very effective, but the cost limits its widespread use, especially in developing countries, such as India where the initial cost is 8,100 rupees. Reference: Medscape Ob/Gyn & Women's Health . 2004;9(1).